Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.

This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.

Let's improve
clinical trial diversity

Consider enrolling

Advancing Health Equity

At Exelixis, we know that clinical trial research doesn't always include participants from a diverse patient population.

We are dedicated to finding solutions that will increase the number of patients from underserved communities in all phases of clinical trials supported and sponsored by Exelixis.

There's Work to Do

Cancer is a disease that can affect anyone. However, it doesn’t affect all people the same.1 For example, cancer is the number one leading cause of death in Asian and Hispanic communities, compared to the number two cause of death among all Americans.2

Certain groups in the U.S. are more highly burdened by cancer due to their race, ethnicity, income level, or insurance coverage. Right now, cancer clinical trials do not include enough people from all of these communities.1

There is a lot of work to do, and we are just getting started. A first step is to ensure that all patients who are appropriate for clinical trials—regardless of income, insurance, race, or ethnicity—have the information they need to consider enrolling in a clinical trial.1

Cancer Clinical Trials Include
Few Black and Hispanic People

Black men 37.4% White men 17.9% 2.2x more likely to die Black men 37.4% White men 17.9% 2.2x more likely to die Black men 37.4% White men 17.9% 2.2x more likely to die

Hispanic and Black people with cancer are less represented in clinical trials compared to their representation in the overall U.S. population.3,4

Prostate Cancer Risk for Underrepresented Men

Prostate cancer is the most commonly diagnosed cancer among men in the United States.5

Black men are at an increased risk for developing and dying of prostate cancer compared to White men. In 2022, it is estimated that 41,600 Black men will be diagnosed with prostate cancer and more than 6,000 Black men are expected to die of the disease.6 Only 4% of men in prostate cancer clinical trials sponsored by pharmaceutical companies are Black, although Black men represent 15% of the prostate cancer population in the U.S.7

Lifetime Risk of Prostate Cancer by Ethnicity6,8

life time risk

Is This Trial Right for You?

If you are living with metastatic castration-resistant prostate cancer, you may be eligible for our clinical trial.

Still unsure? Talk with your doctor about your treatment options. For trial-specific questions, please reach out to Exelixis Medical Information at 1-888-393-5494 or by emailing We can answer your questions associated with participating in the CONTACT-02 clinical trial.

More Information

If you’d like to learn more, here’s where to start:

Discussion Guide

To find out more about participating, download the CONTACT-02 discussion guide and talk to your doctor.